Bayart E, Azria D, Balosso J, Benderitter M, Cohen-Jonathan Moyal E, Delpon G, Deutsch E, Dutreix M, Lacornerie T, Romeo P H, Marchesi V, Maingon P
Société française de radiothérapie oncologique, 47, rue de la Colonie, 75013 Paris, France.
Pôle radiothérapie oncologique, Institut régional du cancer de Montpellier, 208, avenue des Apothicaires, 34298 Montpellier, France.
Cancer Radiother. 2019 Oct;23(6-7):609-616. doi: 10.1016/j.canrad.2019.07.155. Epub 2019 Aug 24.
The ambition of the RADIOTRANSNET network, launched by the INCa at the end of 2018, is to create a French research consortium dedicated to preclinical radiotherapy to foster scientific and clinical interactions at the interface of radiotherapy and radiobiology, and to identify research priorities dedicated to innovation in radiotherapy. The activities of the network are organized around four major axes that are target definition, normal tissue, combined treatments and dose modelling. Under the supervision of the Scientific Council, headed by a coordinator designated by the SFRO and a co-coordinator designated by the SFPM, three leaders coordinate each axis: a radiation-oncologist, a medical physicist and a biologist, who are responsible for organizing a scientific meeting based on the consensus conference methodology to identify priority issues. The selected themes will be the basis for the establishment of a strategic research agenda and a roadmap to help coordinate national basic and translational research efforts in oncological radiotherapy. This work will be published and will be transmitted to the funding institutions and bodies with the aim of opening dedicated calls to finance the necessary human and technical resources. Structuration of a preclinical research network will allow coordinating the efforts of all the actors in the field and thus promoting innovation in radiotherapy.
由法国国家癌症研究所（INCa）于2018年底发起的RADIOTRANSNET网络的目标是创建一个致力于临床前放射治疗的法国研究联盟，以促进放射治疗与放射生物学交叉领域的科学和临床互动，并确定放射治疗创新的研究重点。该网络的活动围绕四个主要轴展开，即靶区定义、正常组织、联合治疗和剂量建模。在由法国放射肿瘤学会（SFRO）指定的协调员和法国医学物理学会（SFPM）指定的联合协调员领导的科学委员会监督下，三位负责人协调每个轴：一位放射肿瘤学家、一位医学物理学家和一位生物学家，他们负责根据共识会议方法组织一次科学会议，以确定优先问题。选定的主题将作为制定战略研究议程和路线图的基础，以帮助协调国家在肿瘤放射治疗方面的基础研究和转化研究工作。这项工作将予以发表，并传达给资助机构和团体，以便开设专门的资助项目，为所需的人力和技术资源提供资金。构建一个临床前研究网络将有助于协调该领域所有参与者的努力，从而促进放射治疗的创新。
